Ropinirole for restless legs syndrome
Identifieur interne : 003462 ( Istex/Curation ); précédent : 003461; suivant : 003463Ropinirole for restless legs syndrome
Auteurs : William Ondo [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-01.
English descriptors
Abstract
Restless legs syndrome (RLS) is a common and underdiagnosed condition that results in a desire to move the extremities often associated with paresthesia/dysesthesia, motor restlessness, worsening of symptoms at rest with at least temporary relief by activity, and worsening of symptoms in the evening or night. We tested the new dopamine agonist ropinirole in 16 patients with RLS in an open‐label trial. The mean daily dose was 2.8 ± 2.3 mg (range, 0.5–12.0). The 13 patients who completed the study reported a 58.7% improvement (p = 1.08 × 10−8) as judged by the abbreviated International Restless Legs Study Group questionnaire. Three patients discontinued the medication secondary to adverse events (rash and nervousness) and other extenuating circumstances. These encouraging preliminary results justify larger and more controlled trials of ropinirole in patients with RLS.
Url:
DOI: 10.1002/1531-8257(199901)14:1<138::AID-MDS1023>3.0.CO;2-A
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003462
Links to Exploration step
ISTEX:8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole for restless legs syndrome</title><author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199901)14:1<138::AID-MDS1023>3.0.CO;2-A</idno><idno type="url">https://api.istex.fr/document/8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003462</idno><idno type="wicri:Area/Istex/Curation">003462</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ropinirole for restless legs syndrome</title><author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-01">1999-01</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="138">138</biblScope><biblScope unit="page" to="140">140</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053</idno><idno type="DOI">10.1002/1531-8257(199901)14:1<138::AID-MDS1023>3.0.CO;2-A</idno><idno type="ArticleID">MDS1023</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonists</term><term>Restless legs syndrome</term><term>Ropinirole</term><term>Sleep disorders</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Restless legs syndrome (RLS) is a common and underdiagnosed condition that results in a desire to move the extremities often associated with paresthesia/dysesthesia, motor restlessness, worsening of symptoms at rest with at least temporary relief by activity, and worsening of symptoms in the evening or night. We tested the new dopamine agonist ropinirole in 16 patients with RLS in an open‐label trial. The mean daily dose was 2.8 ± 2.3 mg (range, 0.5–12.0). The 13 patients who completed the study reported a 58.7% improvement (p = 1.08 × 10−8) as judged by the abbreviated International Restless Legs Study Group questionnaire. Three patients discontinued the medication secondary to adverse events (rash and nervousness) and other extenuating circumstances. These encouraging preliminary results justify larger and more controlled trials of ropinirole in patients with RLS.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003462 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 003462 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:8ABD8E2D2C2A41E42B4833BDD8BE586945DC6053
|texte= Ropinirole for restless legs syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |